Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
The Journal of Rheumatology|August 1, 2022
The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort StudyAnne C Regierer, Anja Weiß, Uta Kiltz, et al.
RMD Open|December 19, 2023
Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trialMichaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Arthritis Research & Therapy|December 14, 2019
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extensionMark C Genovese, Josephine Glover, Maria Greenwald, et al.
Clinical and Experimental Rheumatology|July 15, 2020
ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritisChristof Specker, Annette Alberding, Martin Aringer, et al.
Arthritis Research & Therapy|May 19, 2005
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximabXenofon Baraliakos, Joachim Listing, Jan Brandt, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyMark C Genovese, Patrick Durez, Hanno B Richards, et al.
The Journal of Rheumatology|January 17, 2014
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled studyMark C Genovese, Patrick Durez, Hanno B Richards, et al.
European Radiology|January 25, 2017
Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial settingJohn C Waterton, Meilien Ho, Lars H Nordenmark, et al.
The Lancet. Rheumatology|January 22, 2024
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trialMichaela Koehm, Tanja Rossmanith, Ann C Foldenauer, et al.
Clinical and Experimental Rheumatology|April 27, 2019
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)Thomas Dörner, Hendrik Schulze-Koops, Gerd-Rüdiger Burmester, et al.
Pageof 4